Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Neoadjuvant atezolizumab plus bevacizumab prior liver transplantation for hepatocellular carcinoma

JHEP Reports(2024)10.1016/j.jhepr.2024.101246Source: DataRank Database

Neoadjuvant atezolizumab plus bevacizumab prior liver transplantation for hepatocellular carcinoma is a research paper published in JHEP Reports (2024). On theSindex it has a DataRank of 0. It has been cited 21 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access21 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (6 grants)Impact (FWCI 5.00)OA: goldTopics (24)IDs (PubMed, PMC, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (13)

Rebecca Marino ORCID,Sherrie Bhoori ORCID,Marcus Zeitlhoefler ORCID,Neil Mehta ORCID,Vanessa Banz ORCID

Live enrichment

PubMed:39911942 PMC:PMC11794155 OpenAlex:https://openalex.org/W4403532354

NCI NIH HHS

Grant: R01 CA273932

NIDDK NIH HHS

Grant: R01 DK056621

NIDDK NIH HHS

Grant: R01 DK128289

National Institutes of Health

Grant: 1R01DK128289-01

Hepatic stellate cells in NASH fibrosis and HCC

European Commission

Grant: 101136622

TUMOUR-HOST INTERACTIONS IN LIVER CANCER OF CHILDHOOD AND ADULTS

National Institutes of Health

Grant: 5R01CA273932-03

Determinants of immunotherapy response in NASH-Hepatocellular carcinoma

FWCI

5.00

Citation Percentile

1.0%

Influential Citations

Citation Trend

2025

2026

goldLicense: CC BY NC ND

journalhttps://www.jhep-reports.eu/article/S2589-5559(24)00250-7/pdf

GOLDhttps://doi.org/10.1016/j.jhepr.2024.101246

publisherhttps://www.jhep-reports.eu/article/S2589-5559(24)00250-7/pdf

publisherhttps://api.elsevier.com/content/article/PII:S2589555924002507?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2589555924002507?httpAccept=text/plain

Fields of Study

Hepatocellular Carcinoma Treatment and PrognosisCholangiocarcinoma and Gallbladder Cancer StudiesOrgan Transplantation Techniques and OutcomesMedicine03 medical and health sciences0302 clinical medicine

Keywords

AtezolizumabBevacizumabHepatocellular carcinomaLiver transplantationMedicineOncologyTransplantationInternal medicineChemotherapyCancerNivolumabImmunotherapyDownstagingImmune Checkpoint InhibitorsShort CommunicationDownstaging; Immune Checkpoint Inhibitors; atezolizumab; bevacizumab; hepatocellular carcinoma; immunotherapy; liver transplantationRC799-869Diseases of the digestive system. Gastroenterology

Sustainable Development Goals

SDG 0: Zero hunger